18F F AraG - CellSight Technologies
Alternative Names: 2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine; 18[F]F-AraG; 18F-AraG; [18F]F-ARAG PET; AraG-18[F]F; F18F-AraG; Flourine-18 labelled arabino furanosyl guanine - CellSight Technologies; Fluorine F 18 Ara-G; VisAcTLatest Information Update: 18 Jun 2024
At a glance
- Originator Stanford University
- Developer Boehringer Ingelheim; CellSight Technologies; Checkmate Pharmaceuticals; Stanford University; University of California at San Francisco; University of Pittsburgh
- Class Arabinonucleosides; Furans; Imaging agents; Purines; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
- No development reported Bladder cancer; Cancer; COVID 2019 infections; Head and neck cancer; HIV infections
Most Recent Events
- 14 Jun 2024 National Institutes of health plans a clinical trial for Non-small cell lung cancer (Diagnosis) in Netherlands (NCT06457789) (EudraCT-2023-509486-20-00)
- 16 May 2024 M.D. Anderson Cancer Center plans a phase 0 trial for Oesophageal cancer (Diagnosis) in USA (IV, Injection) (NCT06414902)
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(Diagnosis, In the elderly, In adults) in USA (IV)